Clarametyx is a company that develops strategies to target infections caused by biofilms. The company aims to combat these infections and reduce antibiotic resistance through their work.

Clarametyx

Clarametyx Biosciences Inc. is a clinical stage biotechnology company developing immune-enabling biologic therapies to fight life-threatening infections. Our novel technology platform targets the protective barrier around bacteria, known as biofilms.

CARB-X

National Institute of Deafness & Communications Disorders (NIDCD)

Rev1 Ventures

Clarametyx Biosciences

Respiratory infections are a serious challenge in people with #cysticfibrosis, as recurring infections and persistent inflammation can cause severe complications and destroy lung tissue. The Cystic Fibrosis Foundation explains why this population is particularly vulnerable to infection and the research underway to address this challenge, including our own anti-biofilm platform.

It’s encouraging to see #Congress dedicating attention to the challenge of #antimicrobialresistance. A bipartisan roundtable last week addressed a variety of measures that can help address this urgent public health threat, including strategies to support novel #innovation like the work we’re doing at Clarametyx. Read more on the discussion and opportunities to accelerate progress.

This critical statistic illustrates why we need to pursue novel approaches to help reduce the morbidity and mortality associated with #CF. We support the Cystic Fibrosis Foundation’s leadership in advocating for everyone affected by this chronic condition. And we're doing our part to introduce #innovation that could help reduce the severity of respiratory infections and improve quality of living for more people with CF. #cysticfibrosis

Learn more about what the Cystic Fibrosis Foundation and others are doing to support clinical trial progress today on #ClinicalTrialsDay.

Clarametyx leaders David V. Richards, Charles McOsker and Steve St. Onge are looking forward to attending #ESCMIDGlobal in Barcelona to connect with academic and industry leaders who are pursuing innovation in the fight against #infectiousdisease and #antibioticresistance.

Today on this “rare” Leap Day, we support the community in recognizing #RareDiseaseDay. This important observance raises awareness of the need for more attention and solutions for disorders like cystic fibrosis (CF), a rare disease affecting just one in 3,200 people in the US. We are doing our part to support advancements for this community through a clinical trial evaluating whether our novel anti-biofilm technology could address infections associated with CF. Share your support for rare diseases today!

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Aug 7, 2024 3:48 PM	37146fcf
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Aug 7, 2024 3:48 PM	4eaf4cf0
translate crunchbase fundingrounds	general
peers	general	Aug 7, 2024 3:48 PM	fefb1ca7
news basic	general	Aug 7, 2024 3:48 PM	5cbf08cf
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

CLAR

COM:CLARAMETYX

Clarametyx